This low stable response rate has raised concerns about the place of fostamatinib in the algorithm of ITP treatments, with some authors arguing that fostamatinib will probably not replace rituximab, TPO-RA or splenectomy [59]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.